Efficacy of prolonged treatment following combination with ribavirin and interferon for chronic hepatitis type C: A pilot study

Hepatology Research

Volumn 31, Issue 4, 2005, Pages 211-216

  Nomura, Hideyuki ^a   Kashiwagi, Yoichiro ^a   Nakashima, Hisashi ^a   Tanimoto, Hironori ^a   Shimono, Junya ^b   Kajiwara, Eiji ^c   Maruyama, Toshihiro ^d   Yamashita, Nobuyuki ^e   Nagano, Masanori ^e   Higashi, Masashi ^f   Mukai, Tamotsu ^g   Matsui, Yutaka ^h   Hayashi, Jun ⁱ   Kashiwagi, Seizaburo ^j   Ishibashi, Hiromi ^k  

^a Shin Kokura Hospital   (Japan)

^b Saiseikai Yahata Hospital   (Japan)

^c Department of Gastroenterology   (Japan)

^d KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

^e KYUSHU KOSEI NENKIN HOSPITAL   (Japan)

^f National Hospital Organization   (Japan)

^g JR Kyushu Hospital   (Japan)

^h Department of Internal Medicine   (Japan)

ⁱ KYUSHU UNIVERSITY   (Japan)

^j Japanese Red Cross Kyushu Block Blood Center   (Japan)

^k NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

more..

Author keywords

Chronic hepatitis C; Genotype; Prolonged interferon monotherapy; Ribavirin

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; CONSENSUS INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; JAPAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; PILOT STUDY; PRIORITY JOURNAL; VIRUS LOAD;

EID: 21144432219     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hepres.2005.02.005     Document Type: Article

References (20)

1. F. Imazeki O. Yokosuka K. Fukai et al. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study Hepatology 38 2003 493-502
2. A. Arif R.A. Levine S.O. Sanderson et al. Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin Dig Dis Sci 48 2003 1425-1430
3. J. Hayashi M. Ohmiya Y. Kishihara et al. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C Am J Gastroenterol 89 1994 2151-2156
4. H. Nomura Y. Tsuchiya T. Maruyama et al. The effects of a high dose, short course of interferon on hepatitis C J Gastroenterol Hepatol 14 1999 85-89
5. H. Nomura Y. Kimura H. et al. Tada Predictive factors of a response to interferon treatment in chronic hepatitis C J Clin Gastroenterol 23 1996 185-190
6. M.W. Fried M.L. Shiffman K.R. Reddy et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975-982
7. M.P. Manns J.G. McHutchison S.C. Gordon et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial Lancet 358 2001 958-965
8. T. Poynard P. Marcellin S.S. Lee et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus Lancet 352 1998 1426-1432
9. J.G. McHutchison S.C. Gordon E.R. Schiff et al. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C N Engl J Med 339 1998 1485-1492
10. A. Tsubota Y. Arase F. Suzuki et al. High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load J Gastroenterol 39 2004 155-161
11. H. Nomura H. Tanimoto S. Sou et al. Pilot study of prolonged interferon-alpha retreatment in chronic hepatitis C patients with genotype 1b Hepatol Res 27 2003 266-271
12. J.Y.N. Lau G.L. Davis J. Kniffen et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C Lancet 341 1993 1501-1504
13. V.J. Desmet M. Gerber J.H. Hoofnagle et al. Classification of chronic hepatitis: Diagnosis, grading and staging Hepatology 19 1994 1513-1520
14. K. Hayashi Y. Fukuda I. Nakano et al. Prevalence and characterization of hepatitis C virus genotype 4 in Japanese hepatitis C carriers Hepatol Res 25 2003 409-414
15. Y. Arase F. Suzuki A. Tsubota et al. Sustained negativity for HCV-RNA over 24 or more months by long-term interferon therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load Intervirology 47 2004 19-25
16. G.L. Davis J.B. Wong J.G. McHutchison et al. Early virologic response to treatment with peginterferon α-2b plus ribavirin in patients with chronic hepatitis C Hepatology 38 2003 645-652
17. F.J. Castro J.I. Esteban A. Juarez et al. Early detection of nonresponse to interferon plus ribavirin combination treatment of chronic hepatitis C J Viral Hepat 9 2002 202-207
18. L.J. Jeffers W. Cassidy C.D. Howell et al. Peginterferon α-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1 Hepatology 39 2004 1702-1708
19. H. Suzuki T. Tango A multicenter, randomized, controlled clinical trial of interferon αcon-1 in comparison with lymphoblastoid interferon-alpha in patients with high-titer chronic hepatitis C virus infection Hepatol Res 22 2002 1-12
20. H. Nomura H. Tanimoto E. Kajiwara et al. Factors contributing to ribavirin-induced anemia J Gastroentrol Hepatol 19 2004 1312-1317